CAMBRIDGE, Mass., April 22, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the.

First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty.

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

CAMBRIDGE, Mass., April 08, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.

Shares of Vericel (NASDAQ:VCEL) rose 2.2% after the company reported Q1 results.Quarterly Results Earnings per share fell 42.86% year over year to ($0.10), which missed the estimate of ($0.08).Revenue of $26,678,000 higher by 22.32% from the same period last year, which beat the estimate of $26,280,000.Guidance Vericel hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 05, 2020View more earnings on VCELWebcast URL: https://edge.media-server.com/mmc/p/hig7mvszPrice Action Company's 52-week high was at $19.95Company's 52-week low was at $6.78Price action over last quarter: down 6.78%Company Overview Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.See more from Benzinga * Recap: eXp World Holdings Q1 Earnings * Recap: Peapack-Gladstone Financial Q1 Earnings * Recap: Kirby Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Q4 2019 Vericel Corp Earnings Call

Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the UBS Virtual Global Healthcare Conference. Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at.

Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our employees and shareholders, and to comply with state stay-at-home orders, including the Commonwealth of Massachusetts’ Executive Order prohibiting gatherings of more than ten people, its Board of Directors has approved a change in location of its 2020 Annual Meeting of Shareholders to a virtual-only shareholders meeting instead of an in-person meeting. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CAMBRIDGE, Mass., Feb. 24, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.

Boston Scientific Corp. became one of the first local medical device firms to cut executive and employee pay as the COVID-19 outbreak cuts into surgical product sales.

Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

Image source: The Motley Fool. Vericel (NASDAQ: VCEL)Q1 2020 Earnings CallMay 05, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the Vericel Corporation's first-quarter 2020 earnings call.

Q1 2020 Vericel Corp Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Vericel Corp. (NASDAQ:VCEL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:15 ...

Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019 Positive Cash Flow for the Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May.